An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer

S. M. Sheen-Chen, F. F. Chou, H. L. Eng, W. J. Chen

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background. Adjuvant treatment for node-negative breast cancer remains controversial. It is important to pick out the high-risk groups who may benefit from adjuvant systemic therapy and avoid the unnecessary additional therapy for the favorable prognostic groups. Methods and Material. Retrospective study of immunohistochemical staining for HLA-DR on tumor cells from paraffin-embedded tissue specimens of 32 patients with node-negative invasive breast cancer at this hospital from 1986 to 1991 was performed with the aim to investigate its prognostic significance. Results. HLA-DR staining was positive in nine (28%) patients and negative in twenty-three (72%) patients. One (11%) was a recurrence, and no (0%) death occurred in the positive group, compared with nine (39%) recurrences and five (22%) deaths in the negative group. The multivariate analysis failed to show that HLA-DR expression is an independent prognostic factor. However, with univariate analysis, the 5-year disease-free survival rate (87%) of the positive group was significantly better than that (35%) of the negative group (p = 0.04). The 5-year overall survival rate (100%) of the positive group was also better than that (66%) of the negative group, but the difference was not statistically significant. Furthermore, when combination of the HLA-DR expression and estrogen receptor status was used, both the 5-year disease- free and overall survival rate (81% and 100%, respectively) of group A (positive staining for either HLA-DR or estrogen receptor and positive staining for both) were significantly better than those (33% and 58%, respectively) of group B (negative staining for both HLA-DR and estrogen receptor). Conclusions. We believe HLA-DR expression may be a promising, additive predictive factor to node-negative breast cancer and deserves further investigation based on these preliminary results.

Original languageEnglish
Pages (from-to)510-515
Number of pages6
JournalSurgery
Volume116
Issue number3
Publication statusPublished - Jan 1 1994
Externally publishedYes

Fingerprint

HLA-DR Antigens
Breast Neoplasms
Estrogen Receptors
Staining and Labeling
Survival Rate
Disease-Free Survival
Cancer Care Facilities
Recurrence
Negative Staining
Paraffin
Therapeutics
Multivariate Analysis
Retrospective Studies
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. / Sheen-Chen, S. M.; Chou, F. F.; Eng, H. L.; Chen, W. J.

In: Surgery, Vol. 116, No. 3, 01.01.1994, p. 510-515.

Research output: Contribution to journalArticle

Sheen-Chen, S. M. ; Chou, F. F. ; Eng, H. L. ; Chen, W. J. / An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. In: Surgery. 1994 ; Vol. 116, No. 3. pp. 510-515.
@article{08822a51323f4cddba0931f3191ce575,
title = "An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer",
abstract = "Background. Adjuvant treatment for node-negative breast cancer remains controversial. It is important to pick out the high-risk groups who may benefit from adjuvant systemic therapy and avoid the unnecessary additional therapy for the favorable prognostic groups. Methods and Material. Retrospective study of immunohistochemical staining for HLA-DR on tumor cells from paraffin-embedded tissue specimens of 32 patients with node-negative invasive breast cancer at this hospital from 1986 to 1991 was performed with the aim to investigate its prognostic significance. Results. HLA-DR staining was positive in nine (28{\%}) patients and negative in twenty-three (72{\%}) patients. One (11{\%}) was a recurrence, and no (0{\%}) death occurred in the positive group, compared with nine (39{\%}) recurrences and five (22{\%}) deaths in the negative group. The multivariate analysis failed to show that HLA-DR expression is an independent prognostic factor. However, with univariate analysis, the 5-year disease-free survival rate (87{\%}) of the positive group was significantly better than that (35{\%}) of the negative group (p = 0.04). The 5-year overall survival rate (100{\%}) of the positive group was also better than that (66{\%}) of the negative group, but the difference was not statistically significant. Furthermore, when combination of the HLA-DR expression and estrogen receptor status was used, both the 5-year disease- free and overall survival rate (81{\%} and 100{\%}, respectively) of group A (positive staining for either HLA-DR or estrogen receptor and positive staining for both) were significantly better than those (33{\%} and 58{\%}, respectively) of group B (negative staining for both HLA-DR and estrogen receptor). Conclusions. We believe HLA-DR expression may be a promising, additive predictive factor to node-negative breast cancer and deserves further investigation based on these preliminary results.",
author = "Sheen-Chen, {S. M.} and Chou, {F. F.} and Eng, {H. L.} and Chen, {W. J.}",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "116",
pages = "510--515",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer

AU - Sheen-Chen, S. M.

AU - Chou, F. F.

AU - Eng, H. L.

AU - Chen, W. J.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Background. Adjuvant treatment for node-negative breast cancer remains controversial. It is important to pick out the high-risk groups who may benefit from adjuvant systemic therapy and avoid the unnecessary additional therapy for the favorable prognostic groups. Methods and Material. Retrospective study of immunohistochemical staining for HLA-DR on tumor cells from paraffin-embedded tissue specimens of 32 patients with node-negative invasive breast cancer at this hospital from 1986 to 1991 was performed with the aim to investigate its prognostic significance. Results. HLA-DR staining was positive in nine (28%) patients and negative in twenty-three (72%) patients. One (11%) was a recurrence, and no (0%) death occurred in the positive group, compared with nine (39%) recurrences and five (22%) deaths in the negative group. The multivariate analysis failed to show that HLA-DR expression is an independent prognostic factor. However, with univariate analysis, the 5-year disease-free survival rate (87%) of the positive group was significantly better than that (35%) of the negative group (p = 0.04). The 5-year overall survival rate (100%) of the positive group was also better than that (66%) of the negative group, but the difference was not statistically significant. Furthermore, when combination of the HLA-DR expression and estrogen receptor status was used, both the 5-year disease- free and overall survival rate (81% and 100%, respectively) of group A (positive staining for either HLA-DR or estrogen receptor and positive staining for both) were significantly better than those (33% and 58%, respectively) of group B (negative staining for both HLA-DR and estrogen receptor). Conclusions. We believe HLA-DR expression may be a promising, additive predictive factor to node-negative breast cancer and deserves further investigation based on these preliminary results.

AB - Background. Adjuvant treatment for node-negative breast cancer remains controversial. It is important to pick out the high-risk groups who may benefit from adjuvant systemic therapy and avoid the unnecessary additional therapy for the favorable prognostic groups. Methods and Material. Retrospective study of immunohistochemical staining for HLA-DR on tumor cells from paraffin-embedded tissue specimens of 32 patients with node-negative invasive breast cancer at this hospital from 1986 to 1991 was performed with the aim to investigate its prognostic significance. Results. HLA-DR staining was positive in nine (28%) patients and negative in twenty-three (72%) patients. One (11%) was a recurrence, and no (0%) death occurred in the positive group, compared with nine (39%) recurrences and five (22%) deaths in the negative group. The multivariate analysis failed to show that HLA-DR expression is an independent prognostic factor. However, with univariate analysis, the 5-year disease-free survival rate (87%) of the positive group was significantly better than that (35%) of the negative group (p = 0.04). The 5-year overall survival rate (100%) of the positive group was also better than that (66%) of the negative group, but the difference was not statistically significant. Furthermore, when combination of the HLA-DR expression and estrogen receptor status was used, both the 5-year disease- free and overall survival rate (81% and 100%, respectively) of group A (positive staining for either HLA-DR or estrogen receptor and positive staining for both) were significantly better than those (33% and 58%, respectively) of group B (negative staining for both HLA-DR and estrogen receptor). Conclusions. We believe HLA-DR expression may be a promising, additive predictive factor to node-negative breast cancer and deserves further investigation based on these preliminary results.

UR - http://www.scopus.com/inward/record.url?scp=0028101493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028101493&partnerID=8YFLogxK

M3 - Article

C2 - 8079182

AN - SCOPUS:0028101493

VL - 116

SP - 510

EP - 515

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 3

ER -